ZyVersa Therapeutics (Nasdaq:ZVSA) - Stock Price, News & Analysis

ZVSA Stock Overview

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.

About the company

ZVSA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($5M)

Makes less than USD$1m in revenue ($0)

+ 2 more risks

ZyVersa Therapeutics, Inc. Competitors

GT Biopharma

NasdaqCM:GTBP

US$5.2m

Fresh Tracks Therapeutics

OTCPK:FRTX

US$5.5m

ProtoKinetix

OTCPK:PKTX

US$5.4m

Longeveron

NasdaqCM:LGVN

US$12.0m

Price History & Performance

Summary of all time highs, changes and price drops for ZyVersa Therapeutics
Historical stock prices
Current Share Price	US$6.08
52 Week High	US$220.85
52 Week Low	US$5.00
Beta	0.58
1 Month Change	-18.90%
3 Month Change	-8.05%
1 Year Change	-96.54%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-99.82%

Recent updates

Shareholder Returns

	ZVSA	US Biotechs	US Market
7D	-3.0%	0.4%	1.0%
1Y	-96.5%	0.9%	21.9%

Return vs Industry: ZVSA underperformed the US Biotechs industry which returned 0.7% over the past year.

Return vs Market: ZVSA underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is ZVSA's price volatile compared to industry and market?
ZVSA volatility
ZVSA Average Weekly Movement	18.2%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ZVSA's share price has been volatile over the past 3 months.

Volatility Over Time: ZVSA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	7	Steve Glover	www.zyversa.com

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZyVersa Therapeutics, Inc. Fundamentals Summary

How do ZyVersa Therapeutics's earnings and revenue compare to its market cap?
ZVSA fundamental statistics
Market cap	US$4.61m
Earnings (TTM)	-US$106.25m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ZVSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZVSA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$106.25m
Earnings	-US$106.25m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-139.89
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ZVSA perform over the long term?

See historical performance and comparison

ZVSA Stock Overview

Rewards

Risk Analysis

ZyVersa Therapeutics, Inc. Competitors

NasdaqCM:GTBP

US$5.2m

OTCPK:FRTX

US$5.5m

OTCPK:PKTX

US$5.4m

NasdaqCM:LGVN

US$12.0m

Price History & Performance

Recent News & Updates

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Recent updates

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease

ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq

European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Less than half of directors are independent

ZyVersa Therapeutics, Inc. Announces Executive Changes

ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board

High number of new directors

No independent directors

ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.

Shareholder Returns

Price Volatility

About the Company

ZyVersa Therapeutics, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue